Structures of the biomarkers investigated as part of the TRIBE-AKI consortium; specifically IFN, IL-1, IL-2, TL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and TNF.
Structures by the Protein Data Bank
The Program of Applied Translational Research (PATR) is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, to the development of clinical studies, and to the design of clinical trials. Our work spans several domains, from biomarker discovery and validation to interventional data science and analytics. Our team is comprised of talented physicians and scientists committed to patient-oriented research and developing solutions in clinical medicine and disease management in the community. The Program aims to combine the creativity, commitment, experience, and skills of our physician-scientists, with the goal of improving the care of our patients.
Clinical diagnosis of acute interstitial nephritis (AIN) is challenging as there are no reliable non-invasive biomarkers and its diagnosis currently requires a kidney biopsy.
Acute interstitial nephritis (AIN) is a common condition characterized by minimal clinical features and slowly worsening kidney function.
Acute kidney disease (AKD) is a condition characterized by sub-acute loss of kidney function.
In the hopes of discovering therapeutic targets for acute kidney injury, which currently has no specific therapy, the NIH/NIDDK has created the Kidney Precision Medicine Program consortium.
There are over 100,000 patients awaiting a kidney transplant, but only 20% will receive one.
Acute kidney injury (AKI) is a risk factor for chronic kidney disease (CKD) and cardiovascular disease (CVD) with several biological processes orchestrating either recovery or progression...
Progression of chronic kidney disease (CKD) in children leads to end stage renal disease (ESRD), which is associated with mortality rates 30-150 times higher than the general pediatric...
Participation in marathons has gained popularity in the United States with up to 1100 marathons and 507, 600 finishers.
Acute kidney injury (AKI) affects up to 20% of hospitalized patients and increases the risk of dying in the hospital by a factor of 10.
This trial will randomize patients with acute kidney injury (AKI) who are receiving a kidney-toxic medication to alerts (highlighting the particular medication) versus usual care.
This trial will use an advanced machine-learning technique known as uplift modeling to target AKI alerts to a subset of patients who are most likely to be benefited by reducing alert...
While AKI carries substantial risk, there remains no therapeutic intervention that can alter the course of AKI once it develops, beyond optimizing usual care.
Our prior research in a mouse model of proteinuric kidney disease revealed upregulation of a protein called histone deacetylase (HDAC)